- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT06990841
- Procès original
Comparaison de deux méthodes de traitement des spermatozoïdes différentes et de leurs effets sur la fragmentation de l'ADN et le développement d'embryons
Une comparaison prospective de deux techniques différentes de préparation des spermatozoïdes sur la préséquence de la fragmentation de l'ADN et du développement d'embryons
The goal of this clinical trial is to learn if the LensHooke CA0 device lowers DNA fragmentation in sperm samples compared to a gradient/swim-up technique.
The main questions it aims to answer are:
- Does the LensHooke® CA0 device reduce DNA fragmentation compared to the gradient/swim-up technique?
- Does the LensHooke® CA0 device improve concentration, motility, and morphology compared to the gradient/swim-up technique?
- Is sibling embryo fertilization and development the same?
- Are pregnancy rates different between the 2 groups?
1 semen sample will be split between the 2 treatment techniques. Half of the partner's egg cohort will be injected via intra-cytoplasmic sperm using sperm processed by one technique and the other half of the cohort will be injected by the sperm processed by the other technique. Both methods will look at DNA fragmentation, concentration, motility, and morphology of the sperm. Both methods will be compared in the resulting embryos looking at fertilization, embryo development and pregnancy rates.
Aperçu de l'étude
Statut
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Richard J Kordus, PhD
- Numéro de téléphone: 864-455-1675
- E-mail: rich.kordus@prismahealth.org
Sauvegarde des contacts de l'étude
- Nom: Patti Parker
- Numéro de téléphone: 864-455-1510
- E-mail: patti.parker@prismahealth.org
Lieux d'étude
-
-
South Carolina
-
Greenville, South Carolina, États-Unis, 29605
- Recrutement
- Prisma Health-Upstate Fertility Center of the Caroliinas
-
Contact:
- Richard J Kordus, PhD
- Numéro de téléphone: 864-455-1675
- E-mail: rich.kordus@prismahealth.org
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Samples with ≥15 M/mL spermatozoa concentration
- Female partner between 18 and 34 years old.
- Minimum of 4 fertilized eggs in gradient/swim prep group and 4 fertilized eggs in the Lenshooke prep group for each patient
Exclusion Criteria:
- Samples with <15 M/mL spermatozoa concentration
- female partner >35 years old
- female patient with recurrent pregnancy loss
- female patient with diminished ovarian reserve
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Gradient / Swim-up vs Lenshooke CA0 Comparaison de l'appareil
|
comparison of DNA damage between the 2 interventions and subsequent embryo development and pregnancy rates |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of sperm with DNA fragmentation
Délai: From enrollment until day after sample collection, approximately 1 month
|
The method is based on the Sperm Chromatin Dispersion (SCD) test (Fernández et al., J. Androl 24:59-66, 2003; Fertil Steril 84:833-842, 2005). Intact unfixed spermatozoa (fresh, frozen/unthawed, diluted or neat samples) are immersed in an inert agarose microgel on a pretreated slide. An initial acid treatment denatures DNA in those sperm cells with fragmented DNA. Following this, the lysing solution removes most of the nuclear proteins, and in the absence of massive DNA breakage produces nucleoids with large halos of spreading DNA loops, emerging from a central core. However, the nucleoids from spermatozoa with fragmented DNA either do not show a dispersion halo or the halo is minimal. Slides are stained with Wright's stain. A minimum of 300 sperm per sample will be counted. The percentage of sperm with fragmented DNA will be calculated by dividing the sperm with small and no halos (fragmented sperm) by the total number of sperm counted. |
From enrollment until day after sample collection, approximately 1 month
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Concentration of sperm per mL
Délai: From enrollment until day after sample collection, approximately 1 month
|
Assessed using a sperm class analyzer - SCA (CASA system) for sperm count. Semen samples will be loaded into 20 microliter depth fixed volume slides. Slides will be placed on the Microoptics SCA machine. Videos will be captured of fields until at least 200 motile sperm are captured. Concentration will be analyzed by counting the number of sperm within each field, corrected for the depth of the chamber, and multipled by the volume of the sample. Concentrations between fields will not vary by more than 15%. |
From enrollment until day after sample collection, approximately 1 month
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Percentage of motile sperm
Délai: From enrollment until day after sample collection, approximately 1 month
|
Assessed using a sperm class analyzer - SCA (CASA system) for sperm motility. Semen samples will be loaded into 20 microliter depth fixed volume slides. Slides will be placed on the Microoptics SCA machine. Videos will be captured of fields until at least 200 motile sperm are captured. Motility will be calculated as the number of motile sperm counted divided by the total number of sperm counted. Types of motility will be noted according to WHO semen analysis groupings, hyperactivation, and kinetic motion parameters. |
From enrollment until day after sample collection, approximately 1 month
|
|
Percentage of Sperm with normal morphology Using Kruger Strict Criteria
Délai: From enrollment until day after sample collection, approximately 1 month
|
10 uL volumes of sperm samples will be placed on pre-stained morphology slides using methylene blue/cresyl violet stain. A minimum of 200 sperm will be counted and assessed for normal vs abnormal sperm morphology using Kruger strict criteria. Percentage of normal sperm will be assessed my dividing the number of normal sperm by the total number of sperm counted. |
From enrollment until day after sample collection, approximately 1 month
|
|
Percentage of egg fertilization
Délai: From enrollment until a week after sample collection, approximately 5 weeks
|
The number of fertilized eggs (zygotes) will be divided by the number of eggs inseminated |
From enrollment until a week after sample collection, approximately 5 weeks
|
|
Numerical score of morphokinetic embryo development
Délai: From enrollment until a week after sample collection, approximately 5 weeks
|
Embryo development will be monitored using a time-lapse incubator. A score will be generated based on when the embryos meets developmental time points. The embryo will receive 2 points for each time point it successfully completes with expected parameters. Embryos will receive 1 point for each time point it completes but outside the expected time parameters. i.e. if an embryo has the first cleavage between 23-25 hours it will receive 2 points. If it cleaves earlier than 23 hours or later than 25 hours it will receive 1 point. The total score an embryo receives will be tallied from the time of insemination until the embryo is frozen. |
From enrollment until a week after sample collection, approximately 5 weeks
|
|
Qualitative embryo grade
Délai: From enrollment until a week after sample collection, approximately 5 weeks
|
All embryos will be graded according to a 3-part grading scale at the time of cryopreservation between days 5 and 7 of culture. The embryo will be given a number score of 1-6 based on the embryo's size, size of the blastocoel fluid cavity, and whether or not it is inside, hatching out, or completely hatched out the zona. Each embryo will get a letter grade for the quality of the inner cell mass either A, B, C, or D. Each embryo will get a second letter grade for the quality of the trophectoderm A, B, C, or D. |
From enrollment until a week after sample collection, approximately 5 weeks
|
|
Percentage of patients that become pregnant and deliver a baby
Délai: From enrollment until a delivery of infant, up to 18 months
|
Calculated by the number of patients that become pregnant (assessed by the presence of a fetal heartbeat 5-6 weeks following embryo transfer) divided by the total number of embryos transferred. Live birth will be calculated by the number of patients that give birth divided by the number of embryos transferred. |
From enrollment until a delivery of infant, up to 18 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Richard Kordus, PhD, Prisma Health-Upstate Fertility Center of the Carolinas
Publications et liens utiles
Publications générales
- Ho CLT, Vaughan-Constable DR, Ramsay J, Jayasena C, Tharakan T, Yap T, Whiteman I, Graham N, Minhas S, Homa ST. The relationship between genitourinary microorganisms and oxidative stress, sperm DNA fragmentation and semen parameters in infertile men. Andrologia. 2022 Mar;54(2):e14322. doi: 10.1111/and.14322. Epub 2021 Nov 24.
- Amor H, Hammadeh ME, Mohd I, Jankowski PM. Impact of heavy alcohol consumption and cigarette smoking on sperm DNA integrity. Andrologia. 2022 Aug;54(7):e14434. doi: 10.1111/and.14434. Epub 2022 Apr 28.
- Cho CL, Agarwal A, Majzoub A, Esteves SC. Clinical utility of sperm DNA fragmentation testing: concise practice recommendations. Transl Androl Urol. 2017 Sep;6(Suppl 4):S366-S373. doi: 10.21037/tau.2017.07.28.
- Rex AS, Aagaard J, Fedder J. DNA fragmentation in spermatozoa: a historical review. Andrology. 2017 Jul;5(4):622-630. doi: 10.1111/andr.12381.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 2295231-1
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .